Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
ProQR Therapeutics N.V. logo

NASDAQ · PRQR

ProQR Therapeutics N.V.

Healthcare · Biotechnology

$1.94

Down-$0.05 (-2.51%)

Updated Sep 11, 2026, 5:01 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
249.67M
P/E ratio
-5.37
Dividend yield
0.00%
52-week range
$1.35 – $2.46
Volume
479.99K
Avg. volume
502.75K

Price performance

PRQR price history

1M range · 20 trading sessions · Daily adjusted prices

PRQR closed at $1.94 after 20 trading sessions, up 4.86% for the selected period.

Last close
$1.94
Period change
+4.86%
Period low
$1.85
Period high
$2.43
Daily close
View OHLC price history
PRQR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$1.96$1.96$1.915$1.94479.99K
Sep 9, 2026$2.05$2.125$1.97$1.99958.27K
Sep 8, 2026$2.07$2.11$2.02$2.05449.2K
Sep 4, 2026$2.06$2.11$2.06$2.07368.46K
Sep 3, 2026$2.16$2.20$2.07$2.09697.4K
Sep 2, 2026$2.15$2.2181$2.12$2.15389.55K
Sep 1, 2026$2.13$2.15$2.07$2.12569.34K
Aug 31, 2026$2.29$2.29$2.12$2.13943.52K
Aug 28, 2026$2.31$2.35$2.275$2.29459.37K
Aug 27, 2026$2.29$2.35$2.24$2.321.29M
Aug 26, 2026$2.38$2.40$2.275$2.35700.03K
Aug 25, 2026$2.42$2.425$2.235$2.382.18M
Aug 24, 2026$2.35$2.46$2.26$2.431.06M
Aug 21, 2026$2.28$2.37$2.26$2.34725.82K
Aug 20, 2026$2.35$2.445$2.1403$2.272.67M
Aug 19, 2026$2.18$2.25$2.1201$2.22981.95K
Aug 18, 2026$1.93$2.16$1.89$2.151.56M
Aug 17, 2026$1.91$2.00$1.90$1.93622.65K
Aug 14, 2026$1.85$1.95$1.83$1.92487.37K
Aug 13, 2026$1.90$1.92$1.84$1.85600.28K

Latest PRQR news

The latest Smart Investors Daily articles mentioning PRQR.

Stock researchCompany · Overview

PRQR research

Overview

Company profile and research snapshot.

Company profile

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.63
Implied upside
—
Analysts
15
PRQR recent ratings
DateFirmRatingTarget
Aug 20, 2026B of A SecuritiesBuy—
Jun 29, 2026Evercore ISI GroupOutperform—
Jun 26, 2026Jones TradingBuy—
Jun 26, 2026Chardan CapitalBuy—
Apr 9, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. AX-0811 is ProQR’s next-generation, AI-discovered investigational RNA editing oligon

Yahoo · Sep 2, 2026

ProQR to Participate in Upcoming Investor Conferences in September 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference – Boston, MA1x1s on Tuesday, September 82026 Cantor Glo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By